{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T06:25:21Z","timestamp":1791267921911,"version":"4.1.0"},"reference-count":20,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T00:00:00Z","timestamp":1143676800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2006,5]]},"abstract":"<jats:sec><jats:title>Objectives<\/jats:title><jats:p>To describe the maternal tolerability of nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland and to determine risk factors for development of significant hepatotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>A retrospective study was carried out of all women prescribed nevirapine as part of combination antiretroviral therapy in pregnancy at three HIV centres in Dublin, Ireland (October 2000 to February 2003). Toxicities experienced were graded according to the Division of AIDS toxicity guidelines for adults. Statistical analysis was performed to determine whether there were differences between those that did and those that did not experience significant hepatotoxicity.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 123 women initiated nevirapine as part of combination antiretroviral therapy in the study period. Eight women developed significant hepatotoxicity, including two women who died from fulminant hepatitis. Women who experienced more severe hepatotoxicity had higher pretreatment CD4 counts (<jats:italic>P=<\/jats:italic>0.01).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>In this cohort, women who experienced more severe hepatotoxicity had higher pretreatment CD4 counts, lending additional weight to the need for caution in using nevirapine as part of combination antiretroviral therapy in women not requiring antiretroviral therapy for their own health.<\/jats:p><\/jats:sec>","DOI":"10.1111\/j.1468-1293.2006.00369.x","type":"journal-article","created":{"date-parts":[[2006,3,30]],"date-time":"2006-03-30T12:16:28Z","timestamp":1143720988000},"page":"255-260","source":"Crossref","is-referenced-by-count":63,"title":["Maternal hepatotoxicity with nevirapine as part of combination antiretroviral therapy in pregnancy"],"prefix":"10.1111","volume":"7","author":[{"given":"F","family":"Lyons","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S","family":"Hopkins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B","family":"Kelleher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A","family":"McGeary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Sheehan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Geoghegan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C","family":"Bergin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"FM","family":"Mulcahy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"PA","family":"McCormick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2006,3,30]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)14341-3"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.288.2.189"},{"key":"e_1_2_5_4_2","doi-asserted-by":"publisher","DOI":"10.1086\/367898"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1468-1293.2001.00059.x"},{"key":"e_1_2_5_6_2","article-title":"National Guidelines for the Management of HIV\u20101 in Pregnancy","author":"Lyons F","journal-title":"Irish Medical Journal"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.36130"},{"key":"e_1_2_5_8_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200407010-00002"},{"key":"e_1_2_5_9_2","unstructured":"LyonsF HopkinsS McGearyAet al. Nevirapine tolerability in HIV infected women in pregnancy \u2013 a word of caution.2nd International AIDS Society Conference on HIV Pathogenesis and Treatment. Paris France July 2003 [Abstract LB27]. Available athttp:\/\/www.ias.se\/abstract"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(00)81744-8"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200402010-00003"},{"key":"e_1_2_5_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcfm.2004.10.019"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.4314\/eamj.v81i10.9238"},{"key":"e_1_2_5_14_2","doi-asserted-by":"publisher","DOI":"10.1136\/sti.78.1.58"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.283.1.74"},{"issue":"4","key":"e_1_2_5_16_2","first-page":"S12","article-title":"on behalf of the FTC\u2010302 Study Investigators and the FTC\u2010302 Independent Clinical Steering Committee. Severe liver toxicity in patients receiving two nucleoside analogues and a non\u2010nucleoside reverse transcriptase inhibitor","volume":"14","author":"Sanne I.","year":"2000","journal-title":"AIDS"},{"key":"e_1_2_5_17_2","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200309011-00005"},{"key":"e_1_2_5_18_2","doi-asserted-by":"crossref","first-page":"2096","DOI":"10.1086\/324088","article-title":"Sex differences in nevirapine rash","volume":"33","author":"Bershoff\u2010Matcha SJ","year":"2001","journal-title":"Clin Infect Dis"},{"key":"e_1_2_5_19_2","unstructured":"AweeksF LizakP FrenkelLet al. (PACTG 1022 Study Team) Steady state nevirapine pharmacokinetics during second and third trimester pregnancy and postpartum: PACTG 1022.11th Conference on Retroviruses and Opportunistic Infections. San Francisco CA February 2004 [Abstract 932]."},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-004-0769-5"},{"key":"e_1_2_5_21_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200201250-00020"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1468-1293.2006.00369.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1468-1293.2006.00369.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,10]],"date-time":"2023-10-10T18:32:48Z","timestamp":1696962768000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1468-1293.2006.00369.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,3,30]]},"references-count":20,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,5]]}},"alternative-id":["10.1111\/j.1468-1293.2006.00369.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1468-1293.2006.00369.x","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,3,30]]}}}